RhumbLine Advisers’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

RhumbLine Advisers’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-47,127	Closed	-$5.06M	–	4397
2023 Q1	$5.06M	Buy	47,127 +3,056	+7%	+$352K	0.01%	1304
2022 Q4	$4.85M	Buy	44,071 +6,035	+16%	+$391K	0.01%	1293
2022 Q3	$2.25M	Buy	38,036 +4,703	+14%	+$215K	﹤0.01%	1691
2022 Q2	$941K	Sell	33,333 -3,844	-10%	-$111K	﹤0.01%	2169
2022 Q1	$1.4M	Buy	37,177 +1,226	+3%	+$48.5K	﹤0.01%	1983
2021 Q4	$1.42M	Buy	35,951 +25,057	+230%	+$784K	﹤0.01%	2059
2021 Q3	$258K	Buy	10,894 +525	+5%	+$12.4K	﹤0.01%	2826
2021 Q2	$255K	Buy	+10,369	New	+$231K	﹤0.01%	2853

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

RhumbLine Advisers's RXDX Position: Q2 2023 in Review

RhumbLine Advisers sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 47,127 shares — an estimated $5.06M sold.

RhumbLine Advisers first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $5.06M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

RhumbLine Advisers reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
RhumbLine Advisers sold 47,127 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.06M.
RhumbLine Advisers first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
RhumbLine Advisers's Prometheus Biosciences, Inc. Common Stock position peaked at $5.06M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.